Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2005 3
2006 3
2007 5
2008 5
2009 1
2010 2
2011 1
2013 1
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Lenalidomide and its role in the management of multiple myeloma.
Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, Palumbo A. Falco P, et al. Expert Rev Anticancer Ther. 2008 Jun;8(6):865-74. doi: 10.1586/14737140.8.6.865. Expert Rev Anticancer Ther. 2008. PMID: 18533796 Review.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Bringhen S, D'Agostino M, Paris L, Ballanti S, Pescosta N, Spada S, Pezzatti S, Grasso M, Rota-Scalabrini D, De Rosa L, Pavone V, Gazzera G, Aquino S, Poggiu M, Santoro A, Gentile M, Baldini L, Petrucci MT, Tosi P, Marasca R, Cellini C, Palumbo A, Falco P, Hájek R, Boccadoro M, Larocca A. Bringhen S, et al. Among authors: falco p. Haematologica. 2020 Jul;105(7):1937-1947. doi: 10.3324/haematol.2019.226407. Epub 2019 Oct 3. Haematologica. 2020. PMID: 31582542 Free PMC article. Clinical Trial.
Cost of illness in patients with multiple myeloma in Italy: the CoMiM study.
Petrucci MT, Calabrese E, Levi A, Federico V, Ceccolini M, Rizzi R, Gozzetti A, Falco P, Lazzaro C, Martelli E, Boccadoro M, Lauria F, Liso V, Cavo M, Foa R. Petrucci MT, et al. Among authors: falco p. Tumori. 2013 Jul-Aug;99(4):e193-202. doi: 10.1177/030089161309900434. Tumori. 2013. PMID: 24326862
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T, Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M; Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto. Palumbo A, et al. Among authors: falco p. Blood. 2007 Apr 1;109(7):2767-72. doi: 10.1182/blood-2006-08-042275. Blood. 2007. PMID: 17148584 Free article. Clinical Trial.
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Palumbo A, Avonto I, Bruno B, Falcone A, Scalzulli PR, Ambrosini MT, Bringhen S, Gay F, Rus C, Cavallo F, Falco P, Massaia M, Musto P, Boccadoro M. Palumbo A, et al. Among authors: falco p. Clin Lymphoma Myeloma. 2006 May;6(6):475-7. doi: 10.3816/CLM.2006.n.028. Clin Lymphoma Myeloma. 2006. PMID: 16796778 Clinical Trial.
27 results